The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The jnc 7 report
On average, trial patients lost 8.6% to 12.6% of their body weight, or 19.8 to 29.3 pounds, after 26 weeks of taking orforglipron, compared to 2%, or 4.6 pounds, among those administered the placebo
L., Stevenson, D
Curious for the inside scoop, I compared both so you don't have to
The second infusion dose should be repeated until transaminase levels are falling, there is no detectable paracetamol and the patient is clinically improving
Brello prescribes branded semaglutide and tirzepatide in standard FDA-approved formulations and doses